Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q1 2016 · 10-Q
Revenue$7.74M$7.74M−10.9% vs Q1 2015 Net Income-$253.11K-$253.11KN/M vs Q1 2015 EPS Diluted-$0.02-$0.02— vs Q1 2015 Operating Income-$500,583N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
Free Cash Flowderived$525,430−72.7% Margins · derivedOperating margin-6.5%−6.5 pt vs Q1 2015
Net margin-3.3%−3.8 pt vs Q1 2015
ended Mar 31, 2016 · filed May 13, 2016 · 43 d after period end